TALZENNA® (talazoparib)| About | gBRCA Testing | Identifying Patients

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

About

TALZENNA MoA

Talzenna MoA

gBRCA testing

Identifying patients

Guidelines

Study design

Baseline characteristics

Efficacy & Safety

TALZENNA efficacy

Primary endpoint & subgroup analysis

Secondary endpoints: ORR

Secondary endpoint: OS

Exploratory endpoints: DoR & TTR

TALZENNA safety

Safety and tolerabillity

Adverse events

Patient-reported outcomes with TALZENNA

Patient-reported outcomes

GHS/QoL

Breast symptoms

Dosing

Dose recommendation and special populations

Dose modifications/management

Patient Profiles

Prescribing Information

Support & Resources

Materials

Elevate

Personalising Breast Cancer Treatment

Understanding and Optimising PARP Inhibitors for mBC

PARP Inhibitors in mBC: the role of Real World Evidence

It is important to test early for gBRCA mutations to inform treatment planning^1,2

Patients with BRCA-mutated HER2- LA/mBC received more chemotherapy-based combination regimens and experienced more adverse events than patients with BRCA wild-type^3*

Many patients are at risk

A retrospective real-world analysis of patients with gBRCA-mutated HER2- LA/mBC showed:^4†

37%

had no known family history of BRCA-related cancers

65%

had HR+/HER2- disease

55 y

mean age

gBRCA testing remains low: only 1 of 4 HER2- LA/mBC patients received testing in the EU^5‡

Testing for gBRCA mutations in patients with mBC helps inform treatment planning^1,2

TNBC

HR+/HER2-

TALZENNA^®is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.⁶

Image is for illustrative purposes only.

BRCA=breast cancer susceptibility gene; ESMO=European Society for Medical Oncology; gBRCA=germline breast cancer susceptibility gene; HER2-=human epidermal growth factor receptor 2 negative; HR+=hormone receptor-positive; LA/mBC=locally advanced/metastatic breast cancer; mBC=metastatic breast cancer; NCCN=National Comprehensive Cancer Network; PARP=poly (ADP-ribose) polymerase; PFS=progression-free survival; TNBC=triple-negative breast cancer.

According to a retrospective real-world analysis of BRCA1/2 testing (somatic and/or germline), treatment patterns, and outcomes among 6161 HER2-LA/mBC patients in Germany, France, Italy, Spain, the UK, and the US between 2015 and 2017.³

According to a retrospective real-world analysis of patient demographics, treatment patterns, and safety outcomes among 512 patients with BRCA1/2-mutated HER2- LA/mBC in Germany, France, Italy, Spain, and the US between September 2019 and April 2020.⁴

According to a retrospective real-world analysis of gBRCA1/2 testing among 2624 HER2- LA/mBC patients in Germany, France, Italy, Spain, Israel, and the US between 2019 and 2020.⁵

Explore more

EMSO GUIDELINES

References:

Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V.3.2024 © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Ann Oncol. 2020;31(12):1623-1649.

Niyazov A, Quek RGW, Lewis K, Kemp J, Rider A. BRCA status, treatment patterns, and outcomes in HER2-negative advanced breast cancer: a multi-country real-world study. Poster presented at: ESMO Breast Cancer Annual Congress; May 2-4, 2019; Berlin, Germany. Poster 161P.

Mahtani R, Niyazov A, Lewis K, et al. Patient demographics, treatment patterns and hematologic toxicities among patients with HER2- advanced breast cancer (ABC) and BRCA1/2 mutation(s): a multi-country real-world study. Poster presented at: ESMO Breast Cancer Virtual Meeting; May 23-24, 2020. Poster 669.

Mahtani R, Niyazov A, Lewis K, et al. Germline BRCA1/2 (gBRCA1/2) mutation testing patterns among oncologists treating HER2- advanced breast cancer (ABC): results from a multi-country real-world study. Poster presented at: ESMO Breast Cancer Virtual Annual Meeting; May 23-24, 2020. Poster 652.

TALZENNA^® Summary of Product Characteristics.

Legal Category: S1A
Further information is available upon request

PP-TAL-IRL-0106 May 2024

gBRCA testing

Significantly longer PFS

Superior to chemotherapy in delaying disease progression⁶

See the data

Mechanism of action

Targeted treatment leads to cancer cell death via PARP inhibition and trapping⁶

Explore more

TALZENNA Summary of Product Characteristics

Product Characteristics

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

PP-UNP-IRL-0832. October 2024

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0832. October 2024